Meta-analysis links GLP-1 drugs to lean mass loss but not bone loss

A new systematic review and meta-analysis published in the journal Drugs pooled data from 60 studies covering more than 1.25 million people to examine how GLP-1 receptor agonists affect bones, muscles, and joints ^[1]. The researchers found no meaningful effect on bone mineral density or fracture risk at any body site, and no change in osteoarthritis symptoms measured by the WOMAC index, which tracks pain, stiffness, and physical function ^[1]. But they did find a consistent reduction in lean body mass and fat-free mass among people taking these drugs ^[1].

The analysis combined 46 randomized controlled trials, 13 real-world evidence studies, and one pharmacovigilance study ^[1]. It covered multiple GLP-1 drugs, including semaglutide, liraglutide, exenatide, dulaglutide, and tirzepatide, which combines GLP-1 and GIP receptor activity ^[1]. For muscle outcomes, the researchers analyzed 28 studies and found a standardized mean difference of -0.52 for lean body mass and fat-free mass, a result that held up across multiple sensitivity checks ^[1]. The effect was strongest for liraglutide and semaglutide, and appeared when these drugs were compared with placebo ^[1]. The study authors reported no evidence of publication bias in their findings ^[1].

The researchers rated the certainty of evidence for the muscle-loss finding as low, according to the GRADE framework used to grade the strength of scientific evidence ^[1]. They wrote that the reductions in lean mass appeared largely tied to overall weight loss, since GLP-1 drugs cause people to lose both fat and muscle as they shed pounds ^[1]. The study's authors said it remains uncertain whether this loss of lean mass actually translates into reduced muscle strength or physical performance in daily life ^[1]. They called for further research using muscle function and strength tests, along with statistical models that better account for other factors that could explain the results ^[1].

Why it matters for patients

For people currently taking or considering semaglutide (sold as Ozempic, Wegovy, or Rybelsus) or liraglutide, this research offers some reassurance about bone health. The analysis found no signal that these drugs weaken bones or raise fracture risk, which had been a concern given how much weight some patients lose on these medications ^[1].

At the same time, the study confirms that lean mass loss is a real and consistent finding across a large body of research, not just an isolated observation ^[1]. Because muscle mass matters for strength, mobility, and metabolic health, especially as people age, this finding is relevant to anyone on these medications for an extended period. However, the study's authors were careful to note that losing lean mass on a scale or scan is not the same as losing muscle strength or function in real life, and that link has not yet been established with the same level of evidence ^[1].

The low certainty rating attached to the muscle finding is also important context. It means the current evidence, while consistent, has limitations that could change as more targeted research becomes available. Patients weighing these medications may want to understand that the science on lean mass changes is still evolving, and that researchers themselves say more study is needed before drawing firm conclusions about what this means for daily physical function ^[1].

What happens next

The study's authors called for additional research specifically measuring muscle strength and physical performance, not just lean mass on scans, along with statistical approaches that better account for confounding factors ^[1]. No specific timeline for that follow-up research was given in the study ^[1]. The full protocol and methods for this meta-analysis were registered in advance and are publicly available through the Open Science Framework ^[1].